Welcome to the After-On podcast. I'm your host, Rob Reed.

And this is a series of conversations with thinkers, founders, and scientists.

Take a little time and stretch out because these talks are unhurry and meant to bring you

to a top percentile understanding of something important.

Also, whether you're ready to start up score ideas, a techie or a lit major, take your

time, engage your mind, and you'll be glad you did.

Especially this week when we'll be talking to...

Rick Doblin, who has been working since the 80s to bring the world a new approach to

psychiatric therapy.

And after decades of relentlessly amassing evidence and patiently winning over medical

regulators worldwide, he seems to be on the cusp of success.

This is part two of my conversation with Rick.

Part one went up exactly a week ago.

If you haven't heard it yet, you probably want to give it a listen first.

It should be positioned adjacent to this episode in your podcast player.

If it isn't, you can find it on my website, which is at after-on.com.

Or you could probably get away with listening to this part first, with a bit of context

that'll give you in a moment.

This is the more storytelling and prognosticating half of my interview with Rick.

We talk about his unbelievably long, strange and wonderful journey through life, as well

as the much longer and even stranger history of the molecule that he and his team seem

to be on the cusp of getting FDA approval for, along with approval from the top drug

...